首页> 外文期刊>Endocrine-related cancer >ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer
【24h】

ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer

机译:ID4控制正常乳腺上皮中的腔系血统,并抑制基底样乳腺癌中的BRCA1功能

获取原文
           

摘要

Inhibitor of differentiation (ID) proteins are key regulators of development and tumorigenesis. One member of this family, ID4, controls lineage commitment during mammary gland development by acting upstream of key developmental pathways. Recent evidence suggests an emerging role for ID4 as a lineage-dependent proto-oncogene that is overexpressed and amplified in a subset of basal-like breast cancers (BLBCs), conferring poor prognosis. Several lines of evidence suggest ID4 may suppress BRCA1 function in BLBC and in doing so, define a subset of BLBC patients who may respond to therapies traditionally used in BRCA1-mutant cancers. This review highlights recent advances in our understanding of the requirement for ID4 in mammary lineage commitment and the role for ID4 in BLBC. We address current shortfalls in this field and identify important areas of future research.
机译:分化抑制剂(ID)蛋白是发育和肿瘤发生的关键调节因子。该家族的一个成员ID4通过在关键发育途径的上游起作用来控制乳腺发育过程中的血统承诺。最近的证据表明,ID4作为一种谱系依赖的原癌基因正在发挥作用,该基因在一部分基底样乳腺癌(BLBC)中过度表达和扩增,预后较差。几条证据表明,ID4可能会抑制BLBC中的BRCA1功能,并且这样做可以定义一部分BLBC患者,这些患者可能对传统上用于BRCA1突变癌症的疗法有反应。这篇综述重点介绍了我们对ID4在乳腺谱系承诺中的要求以及ID4在BLBC中的作用的理解方面的最新进展。我们解决了该领域当前的不足,并确定了未来研究的重要领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号